Aquestive Therapeutics (NASDAQ:AQST) Announces Earnings Results, Beats Expectations By $0.04 EPS

Key Points

• Aquestive Therapeutics reported a quarterly EPS of ($0.14), exceeding analysts' expectations of ($0.18) by $0.04.
• Aquestive Therapeutics' stock has a current trading price of $3.86 and a market capitalization of $383.41 million, reflecting a 1.0% decrease on the day.
• Equities analysts have rated the stock with an average rating of "Buy" and an average price target of $10.14, indicating positive investor sentiment.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04, Zacks reports. The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $11.32 million. Aquestive Therapeutics updated its FY 2025 guidance to EPS.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock remained flat at $4.11 during trading on Friday. The stock had a trading volume of 1,701,734 shares, compared to its average volume of 1,235,658. The stock has a market cap of $409.85 million, a price-to-earnings ratio of -5.87 and a beta of 1.99. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80. The firm's 50-day moving average is $3.77 and its two-hundred day moving average is $3.15.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on AQST shares. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $7.00 target price for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $10.14.

Hedge Funds Weigh In On Aquestive Therapeutics

Institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Aquestive Therapeutics by 6.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company's stock valued at $156,000 after purchasing an additional 2,649 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock valued at $31,000 after purchasing an additional 4,134 shares during the last quarter. The Manufacturers Life Insurance Company grew its stake in Aquestive Therapeutics by 16.6% in the second quarter. The Manufacturers Life Insurance Company now owns 32,073 shares of the company's stock valued at $106,000 after purchasing an additional 4,557 shares during the last quarter. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics in the second quarter valued at about $33,000. Finally, Creative Planning grew its stake in shares of Aquestive Therapeutics by 15.3% during the second quarter. Creative Planning now owns 98,751 shares of the company's stock worth $327,000 after acquiring an additional 13,130 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.